Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Other Non Operating Income (2022 - 2025)

Stoke Therapeutics has reported Other Non Operating Income over the past 4 years, most recently at -$110000.0 for Q4 2025.

  • Quarterly results put Other Non Operating Income at -$110000.0 for Q4 2025, down 154.73% from a year ago — trailing twelve months through Dec 2025 was -$51000.0 (up 79.35% YoY), and the annual figure for FY2025 was -$51000.0, up 79.35%.
  • Other Non Operating Income for Q4 2025 was -$110000.0 at Stoke Therapeutics, down from $3000.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for STOK hit a ceiling of $201000.0 in Q4 2024 and a floor of -$428000.0 in Q1 2024.
  • Median Other Non Operating Income over the past 4 years was $41000.0 (2023), compared with a mean of $2187.5.
  • Peak annual rise in Other Non Operating Income hit 390.24% in 2024, while the deepest fall reached 1119.05% in 2024.
  • Stoke Therapeutics' Other Non Operating Income stood at $42000.0 in 2022, then dropped by 2.38% to $41000.0 in 2023, then surged by 390.24% to $201000.0 in 2024, then crashed by 154.73% to -$110000.0 in 2025.
  • The last three reported values for Other Non Operating Income were -$110000.0 (Q4 2025), $3000.0 (Q3 2025), and $28000.0 (Q2 2025) per Business Quant data.